Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Oct 8;3(10):e139. doi: 10.1038/psp.2014.36

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Time- and dose-dependent changes in tumor volume and plasma VEGF produced by tumor and host. (a) Tumor volume changes over time after two weeks of treatment with vehicle or sunitinib at 20, 40, and 80 mg/kg/day in A431 xenograft mice. Treatment began on day 23. (b) Simulated time profile of plasma VEGF produced by tumor after administration of vehicle, 20, 40, and 80 mg/kg/day dose of sunitinib. Corresponding tumor volume changes are shown in a. (c) Comparison of VEGF produced by host and tumor cells, after treatment with sunitinib at 40 and 80 mg/kg/day for two weeks starting at day 23. (d) Total VEGF concentrations and contribution of VEGF produced by host and tumor at the end of the study on day 36.